Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Give money, supplies to help stock Wake County classrooms
Recommended
What to know about Shearon Harris Nuclear Plant, emergency plans
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals Inc
(NQ:
RYTM
)
49.26
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
49.26
Bid (Size)
44.09 (1)
Ask (Size)
49.38 (1)
Prev. Close
49.26
Today's Range
49.26 - 49.26
52wk Range
16.72 - 53.92
Shares Outstanding
60,972,909
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
July 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+9.15%
+9.15%
1 Month
+19.01%
+19.01%
3 Month
+29.26%
+29.26%
6 Month
+20.29%
+20.29%
1 Year
+181.32%
+181.32%
More News
Read More
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 28, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations For Rhythm Pharmaceuticals's Future
April 26, 2024
Via
Benzinga
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
April 10, 2024
Via
Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
February 22, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
The 3 Best Nasdaq Stocks to Buy in May 2024
May 07, 2024
Via
InvestorPlace
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
April 29, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 24, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
April 19, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
April 16, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
April 01, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
Via
MarketBeat
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
March 25, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.